Outcomes

The evidence for acarbose outcomes is primarily derived from completed clinical trials, though specific results are not detailed in the available data. The strength of evidence is limited by the lack of published outcome data from these trials.

Clinical Trial Evidence:
Multiple Phase 3 studies have been completed investigating acarbose:

A completed Phase 3 trial (NCT01177384) evaluated the safety and efficacy of adding sitagliptin to acarbose monotherapy in type 2 diabetes patients
Another completed Phase 3 study (NCT01242202) assessed the safety and efficacy of combining acarbose with ASP1941 in type 2 diabetic patients
A completed study (NCT04665570) examined the safety and efficacy of acarbose combined with metformin in newly diagnosed Indian patients with type 2 diabetes

Bioavailability Studies:
A completed Phase 1 bioequivalence study (NCT01554631) compared orally disintegrating tablets versus standard tablets of acarbose 100mg, suggesting efforts to optimize drug delivery formulations.

Evidence Limitations:
The available evidence does not include specific measurable outcomes such as:

HbA1c reduction percentages
Fasting glucose changes
Postprandial glucose effects
Adverse event rates
Comparative effectiveness data

While multiple well-designed clinical trials have been completed, the absence of published results significantly limits the ability to characterize acarbose's clinical outcomes. The research appears to focus on combination therapies and formulation improvements, suggesting acarbose remains an active area of diabetes treatment research.

Disclaimer: This summary is for informational purposes only and should not replace consultation with healthcare providers for personalized medical advice.

Acarbose

Member access required